Emergent Biosolutions Reports Financial Results For Second Quarter 2021.

SEES Q3 REVENUE $400 MILLION TO $500 MILLION.
Q2 REVENUE $190.9 MILLION.
Q2 REVENUE ESTIMATE $398.9 MILLION -- REFINITIV IBES DATA.
REAFFIRMS 2021 FULL YEAR FORECAST FOR REVENUES AND PROFIT.
Q3 REVENUE VIEW $495.4 MILLION -- REFINITIV IBES DATA.
FY2021 REVENUE VIEW $1.80 BILLION -- REFINITIV IBES DATA.
EMERGENT BIOSOLUTIONS - QTRLY EARNINGS PER SHARE $0.09 ; QTRLY ADJUSTED EARNINGS PER SHARE $0.33.
EMERGENT BIOSOLUTIONS - IN QUARTER, HAD INVENTORY WRITE-OFFS OF $41.5 MILLION.
EMERGENT BIOSOLUTIONS - IN QUARTER,  INVENTORY WRITE-OFFS RELATED TO RAW MATERIALS, IN-PROCESS BATCHES MANUFACTURED AT BAYVIEW FACILITY.
EMERGENT BIOSOLUTIONS - FY OTHER PRODUCT SALES, EXPECTED TO BE IMPACTED ON ASSUMPTION THAT A NEW RAXIBACUMAB CONTRACT TO BE AWARDED LATER THAN PLANNED.